If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the ...

The challenge with curing the Human Immunodeficiency Virus (HIV) is that it tends to hide dormant in cells, evading the ...

According to the new study, HIV achieves this with a tissue-specific approach, cloaking itself in a host cell's DNA by ...

BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and ...

The antibody, called 04_A06, blocked 98.5% of more than 300 different HIV strains in lab tests, including many resistant to ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the ...

Graham Johnson, a computational biologist and scientific illustrator at the Allen Institute for Cell Science, recalls ...

Results from pritelivir Phase 2 study demonstrate a favorable safety profile and a numerically higher lesion healing rate vs. foscarnetPritelivir Phase 2 results supported FDA Breakthrough Therapy ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...

Health officials in Los Angeles County said on Friday they are investigating a possible local spread of a more severe strain ...

Multiple viral infections are common after stem cell transplants, especially in patients with CMV exposure, haploidentical donors, or acute graft-vs-host disease or those receiving T-cell depletion.

Researchers found that among cancer patients getting immunotherapy, those who got an mRNA Covid vaccine within 100 days ...